Iterum Therapeutics (NASDAQ:ITRM) Trading Down 4.2% – Here’s What Happened

Iterum Therapeutics PLC (NASDAQ:ITRM) shares fell 4.2% during trading on Monday . The company traded as low as $0.92 and last traded at $0.92. 564,205 shares were traded during mid-day trading, a decline of 47% from the average session volume of 1,070,151 shares. The stock had previously closed at $0.96.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Iterum Therapeutics in a research note on Thursday, May 8th.

Iterum Therapeutics Trading Down 4.2%

The firm has a market cap of $36.95 million, a price-to-earnings ratio of -0.93 and a beta of 2.79. The stock’s 50 day moving average is $0.99 and its 200 day moving average is $1.28.

Iterum Therapeutics (NASDAQ:ITRM) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.14). On average, equities research analysts predict that Iterum Therapeutics PLC will post -0.86 EPS for the current year.

Institutional Trading of Iterum Therapeutics

A number of institutional investors have recently bought and sold shares of ITRM. Renaissance Technologies LLC bought a new stake in Iterum Therapeutics in the 4th quarter valued at about $777,000. OneDigital Investment Advisors LLC bought a new stake in shares of Iterum Therapeutics during the 1st quarter worth approximately $124,000. Two Sigma Investments LP bought a new stake in shares of Iterum Therapeutics during the 4th quarter worth approximately $45,000. Finally, Citadel Advisors LLC bought a new stake in shares of Iterum Therapeutics during the 4th quarter worth approximately $38,000. Institutional investors own 9.21% of the company’s stock.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.